Riptide Presents Promising Late Preclinical Results at IPF Summit
August 27, 2019
SAN DIEGO, CA. – Riptide Bioscience President Dr. George Martin today delivered a poster presentation at the 2019 IPF Summit, the largest industry event specifically focused on translational programs in Idiopathic Pulmonary Fibrosis.
Dr. Martin’s presentation was entitled “Synthetic Peptides Reprogram M2/Fibrotic Macrophages to M1, Preventing Bleomycin Induced Lung and Skin Fibrosis.” Dr. Martin focused on the remarkable efficacy shown by the “RP class” of peptide therapeutics administered systemically or by inhalation, in animal models of IPF.
Dr. Martin commented, “Fibrotic lesions in IPF contain M2-like macrophages which powerfully drive the fibrotic process, by polarizing fibroblasts to express excess collagen. We’ve shown that RP peptides, targeting a specific domain on these macrophages, can reverse that activity. In a number of animal models, the results appear superior to FDA-approved therapies.” Martin concluded, “We’re believe this approach could have significant clinical benefit. We’re looking forward to early clinical translation for this program.”
Riptide Bioscience, Inc., with laboratories in Vallejo, California, maintains an intensive program of research into peptide-based therapeutics. Contact: email@example.com